BOSTON (Reuters) - The Wyeth drug Rapamune dramatically reduces rare growths known as angiomyolipomas after one year of treatment, but the benefits begin to fade if the transplant drug is discontinued, researchers reported on Wednesday.
A team led by Dr. John Bissler of Cincinnati Children's Hospital Medical Center tested the drug, usually used to stop the rejection of organ and tissue transplants, on 25 volunteers.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!